Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.2% | -24.3% | -5.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.3% | 92.3% | 90.5% | 90.5% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -16.4% | -5.7% | 3.6% | 16.8% |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -9.5% | 1.3% | 2.5% | 12.3% |
| EPS Diluted | -0.32 | 0.044 | 0.11 | 0.58 |
| % Growth | -833.9% | -60.4% | -81% | – |
| Operating Cash Flow | -$0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | $0 | $0 |